71 completed, 22 terminated, 10 active not recruiting, 6 withdrawn. 68 Phase 2, 36 Phase 1, 8 Phase 3, 5 Not applicable, 2 Early Phase 1.
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung Aerosol Sargramostim, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung | Phase 1 | Withdrawn | Mayo Clinic | 2025-10-28 | 2025-08-07 | |
| Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) Cyclophosphamide, Fludarabine - Phase 1, Recurrent Melanoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 39 | 2025-02-25 | 2026-10-05 |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 150 | 2022-12-06 | 2026-10-26 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Pembrolizumab, Talimogene Laherparepvec - Advanced Melanoma, Recurrent Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 43 | 2018-06-05 | 2026-05-20 |
| Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis - Cervical Carcinoma, Esophageal Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2017-11-03 | 2018-10-03 | |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 267 | 2015-09-08 | 2026-10-26 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 59 | 2015-04-08 | 2026-10-07 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2015-01-01 | 2020-07-27 | |
| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations trametinib, laboratory biomarker analysis, pharmacological study - Recurrent Melanoma, Stage IIIB Melanoma | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 9 | 2015-01-01 | 2021-05-28 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery aldesleukin, ipilimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | CINJRegulatory | 9 | 2014-11-26 | 2023-07-18 |
| Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis - Liver Metastases, Lung Metastases | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 8 | 2014-09-05 | 2024-05-21 |
| Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery selinexor, Correlative studies - Recurrent Melanoma | Phase 1 | Completed | Kari Kendra | 8 | 2014-08-22 | 2023-04-04 |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, therapeutic procedure - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | Yale University | 49 | 2014-05-01 | 2020-01-02 |
| Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Terminated | University of Washington | 23 | 2014-03-01 | 2020-02-13 |
| Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery propranolol hydrochloride, Correlative Studies - Male Breast Cancer, Recurrent Melanoma | Early Phase 1 | Completed | William Carson | 1 | 2014-01-21 | 2022-12-06 |
Showing 20 of 111. Sign in to see all of them.
Melanoma (111) · Carcinoma, Renal Cell (12) · Breast Neoplasms (9) · Uveal Melanoma (9) · Brain Neoplasms (7) · Skin Neoplasms (7) · Breast Neoplasms, Male (6) · Colonic Neoplasms (6) · Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Ovarian Neoplasms (5) · Prostatic Neoplasms (5) · Sarcoma (5) · Carcinoma, Hepatocellular (4) · Colorectal Neoplasms (4)
Neoplasms by Histologic Type (111) · Neoplasms by Site (111) · Neoplasms, Germ Cell and Embryonal (111) · Neoplasms, Nerve Tissue (111) · Neuroectodermal Tumors (111) · Nevi and Melanomas (111) · Skin Diseases (111) · Skin and Connective Tissue Diseases (111) · Neuroendocrine Tumors (110) · Neoplasms (105) · Skin Neoplasms (104) · Neoplasms, Glandular and Epithelial (20) · Urogenital Diseases (19) · Urogenital Neoplasms (19) · Female Urogenital Diseases (18)
Ipilimumab (13) · CTLA-4 Antigen (12) · Interleukin-2 (10) · aldesleukin (10) · Biopsy (9) · Cyclophosphamide (7) · Immunohistochemistry (7) · Nivolumab (7) · Sirolimus (7) · Sorafenib (6) · Specimen Handling (6) · montanide ISA 51 (6) · temsirolimus (6) · Bevacizumab (5) · Polymerase Chain Reaction (5)
National Cancer Institute (NCI) (70) · Fred Hutchinson Cancer Center (5) · Mayo Clinic (4) · Roswell Park Cancer Institute (4) · Vanderbilt-Ingram Cancer Center (4) · Abramson Cancer Center at Penn Medicine (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Stanford University (2) · Vical (2) · Albert Einstein College of Medicine (1) · Alliance for Clinical Trials in Oncology (1) · CINJRegulatory (1) · Case Comprehensive Cancer Center (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Jonsson Comprehensive Cancer Center (1)
United States (105) · Canada (8) · Puerto Rico (2) · Australia (1) · Guam (1)
Thomas Gajewski (5) · Ahmad Tarhini (4) · Svetomir Markovic (3) · Cassian Yee (2) · Craig Slingluff (2) · Frank S Hodi (2) · Jeffrey Weber (2) · Keith Flaherty (2) · Kevin Kim (2) · Kim Margolin (2) · Patrick Hwu (2) · Paul Chapman (2) · Siwen Hu-Lieskovan (2) · Sylvia Lee (2) · Wenyin Shi, MD, PhD (2)
PMID 20098694, PMID 20967484, PMID 21631324, PMID 21642685, PMID 23228035, PMID 23248256, PMID 23402397, PMID 23620404, PMID 24047116, PMID 24464266, PMID 24817603, PMID 25250858, PMID 25369488, PMID 25649350, PMID 25797743, PMID 26351350, PMID 26586415, PMID 27269940, PMID 27368067, PMID 28816150, PMID 29784747, PMID 31401903, PMID 31998643, PMID 32192573, PMID 32463741, PMID 32641862, PMID 32692450, PMID 33048619, PMID 33861486, PMID 35133871, PMID 35138919, PMID 35264434, PMID 35659704, PMID 36029412, PMID 36166727, PMID 36351402, PMID 37036756, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38236249, PMID 38591867, PMID 39342463, PMID 39666929, PMID 39693587, PMID 39863139, PMID 39913886, PMID 40132910, PMID 40865033, PMID 41066729
U10CA180820 (6), U10CA021115 (5), N01CM62206 (4), U10CA031946 (4), K12CA076930 (3), P30CA008748 (3), P30CA016056 (3), U10CA032102 (3), U24CA196172 (3), N01CM00070 (2), N01CM00071 (2), N01CM62201 (2), N01CM62202 (2), N01CM62203 (2), N01CM62205 (2)